Liid Pharmaceutical, Inc. is committed to develop ASOs by leveraging our proprietary BROTHERS (BRO) technology, which thermodynamically and kinetically enhances the efficacy and mitigates safety profiles by reducing off-target effects. We strongly believe that ASOs with BRO technology can have potential uses in the treatment of a range of serious and life-threatening human diseases. 

Liid Pharmaceuticals is actively developing a diverse pipeline to address unmet medical needs, such as Gaucher disease (lysosomal storage diseases), MASH (metabolic dysfunction-associated steatotic liver disease, NASH) and heart failure, etc. 
We are also looking forward to collaborating with academia/biotech/pharma.

Liid Pharmaceuticals, Inc.

Org chart

Teams

Offices